These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 34053963)

  • 21. Options for screening for colorectal cancer in the Royal Air Force: a cost-effectiveness evaluation.
    Daniels K; McKee M
    J R Army Med Corps; 1995 Oct; 141(3):142-50. PubMed ID: 8568748
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
    van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
    Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association Between Primary Care Visits and Colorectal Cancer Screening Outcomes in the Era of Population Health Outreach.
    Halm EA; Beaber EF; McLerran D; Chubak J; Corley DA; Rutter CM; Doubeni CA; Haas JS; Balasubramanian BA
    J Gen Intern Med; 2016 Oct; 31(10):1190-7. PubMed ID: 27279097
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Options for screening for colorectal cancer.
    Atkin W
    Scand J Gastroenterol Suppl; 2003; (237):13-6. PubMed ID: 12797674
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of Race and Socioeconomic Status With Colorectal Cancer Screening, Colorectal Cancer Risk, and Mortality in Southern US Adults.
    Warren Andersen S; Blot WJ; Lipworth L; Steinwandel M; Murff HJ; Zheng W
    JAMA Netw Open; 2019 Dec; 2(12):e1917995. PubMed ID: 31860105
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness analysis on screening for colorectal neoplasm and management of colorectal cancer in Asia.
    Tsoi KK; Ng SS; Leung MC; Sung JJ
    Aliment Pharmacol Ther; 2008 Aug; 28(3):353-63. PubMed ID: 18638075
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of Chronic Comorbidities on Follow-up Colonoscopy After Positive Colorectal Cancer Screening Results: A Population-Based Cohort Study.
    Bhatia D; Sutradhar R; Paszat LF; Rabeneck L; Singh S; Tinmouth J; Lipscombe LL
    Am J Gastroenterol; 2022 Jul; 117(7):1137-1145. PubMed ID: 35333781
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Accuracy of self-checked fecal occult blood testing for colorectal cancer in Thai patients.
    Lohsiriwat V
    Asian Pac J Cancer Prev; 2014; 15(18):7981-4. PubMed ID: 25292099
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical impact of the immunochemical fecal occult blood test for colorectal cancer screening in Brazil.
    Teixeira CR; Bonotto ML; Lima JP; Figueiredo LF; Conrado L; Frasca C
    Ann Gastroenterol; 2017; 30(4):442-445. PubMed ID: 28655982
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of guaiac and immunological fecal occult blood tests in colorectal cancer screening: the patient perspective.
    Deutekom M; van Rossum LG; van Rijn AF; Laheij RJ; Fockens P; Bossuyt PM; Dekker E; Jansen JB
    Scand J Gastroenterol; 2010 Nov; 45(11):1345-9. PubMed ID: 20560814
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trends in colonoscopy and fecal occult blood test use after the introduction of dual screening offers in Germany: Results from a large population-based study, 2003-2016.
    Chen C; Stock C; Jansen L; Chang-Claude J; Hoffmeister M; Brenner H
    Prev Med; 2019 Jun; 123():333-340. PubMed ID: 30946858
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rates and correlates of potentially inappropriate colorectal cancer screening in the Veterans Health Administration.
    Powell AA; Saini SD; Breitenstein MK; Noorbaloochi S; Cutting A; Fisher DA; Bloomfield HE; Halek K; Partin MR
    J Gen Intern Med; 2015 Jun; 30(6):732-41. PubMed ID: 25605531
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of screening for colorectal cancer in the general population.
    Frazier AL; Colditz GA; Fuchs CS; Kuntz KM
    JAMA; 2000 Oct; 284(15):1954-61. PubMed ID: 11035892
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The public prefers fecal occult blood test over colonoscopy for colorectal cancer screening.
    Almog R; Ezra G; Lavi I; Rennert G; Hagoel L
    Eur J Cancer Prev; 2008 Oct; 17(5):430-7. PubMed ID: 18714185
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adding familial risk assessment to faecal occult blood test can increase the effectiveness of population-based colorectal cancer screening.
    Dekker N; van Rossum LG; Van Vugt-van Pinxteren M; van Stiphout SH; Hermens RP; van Zelst-Stams WA; van Oijen MG; Laheij RJ; Jansen JB; Hoogerbrugge N
    Eur J Cancer; 2011 Jul; 47(10):1571-7. PubMed ID: 21367600
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protective effect of faecal occult blood test screening for colorectal cancer: worse prognosis for screening refusers.
    Niv Y; Lev-El M; Fraser G; Abuksis G; Tamir A
    Gut; 2002 Jan; 50(1):33-7. PubMed ID: 11772964
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systematic review with meta-analysis: faecal occult blood tests show lower colorectal cancer detection rates in the proximal colon in colonoscopy-verified diagnostic studies.
    Hirai HW; Tsoi KK; Chan JY; Wong SH; Ching JY; Wong MC; Wu JC; Chan FK; Sung JJ; Ng SC
    Aliment Pharmacol Ther; 2016 Apr; 43(7):755-64. PubMed ID: 26858128
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of artificial intelligence to identify subjects with a positive FOBT predicted to be non-compliant with both colonoscopy and harbor cancer.
    Konikoff T; Flugelman A; Comanesther D; Cohen AD; Gingold-Belfer R; Boltin D; Golan MA; Eizenstein S; Dotan I; Perry H; Levi Z
    Dig Liver Dis; 2023 Sep; 55(9):1253-1258. PubMed ID: 37286451
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interval colorectal cancer rates after Hemoccult Sensa and survival by detection mode for individuals diagnosed with colorectal cancer in Winnipeg, Manitoba.
    Decker KM; Nugent Z; Lambert P; Biswanger N; Singh H
    PLoS One; 2018; 13(9):e0203321. PubMed ID: 30180176
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer.
    Dinh T; Ladabaum U; Alperin P; Caldwell C; Smith R; Levin TR
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1158-66. PubMed ID: 23542330
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.